araag2/HINT huggingface dataset:
Clinical trial NCT00042575 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: duloxetine
SMILES: CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  You must be at least 18 years old.

          -  You must be diagnosed with major depressive disorder

          -  You must be able to visit the doctor's office once a week to once every 2 weeks for a
             total of 8 weeks.

        Exclusion Criteria:

          -  You are a woman and are pregnant or breastfeeding.

          -  You have a current or previous major psychiatric disorder other than depression, such
             as bipolar disorder, schizophrenia, or other psychotic disorder.

          -  You have a history of alcohol or drug dependence or abuse within the past 6 months.

          -  You are allergic to the study drug or you have experienced allergic reactions when
             taking several medications at once.

          -  You have a serious medical illness.
Clinical trial NCT00230776 (phase 3, status: completed)
Conditions: fibromyalgia
ICD codes: M79.7
Drugs: pregabalin, placebo
SMILES: NCC1(CC(O)=O)CCCCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must meet the ACR criteria for fibromyalgia (ie, widespread pain present for
             at least 3 months, and pain in at least 11 of 18 specific tender point sites.

          -  Patients must have a score of >40 mm on the Visual Analog Scale

        Exclusion Criteria:

          -  Patients with any widespread inflammatory musculoskeletal disorders, widespread
             rheumatic diseases other than fibromyalgia, active infections, or untreated endocrine
             disorders.
Clinical trial NCT01497834 (phase 3, status: completed)
Conditions: hepatitis c
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: bms-790052 (daclatasvir), bms-650032 (asunaprevir)
SMILES: COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C, COC1=CN=C(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)C2=C1C=CC(Cl)=C2
Eligibility criteria:

        Inclusion Criteria:

          -  Chronic HCV-1b infected patient

          -  HCV RNA viral load of ≥ 100,000 IU/mL at screening

          -  Ages 20 to 75 years

          -  Non-responder to Interferon plus Ribavirin therapy

          -  Patient who has been excluded from interferon/ribavirin therapy or intolerant for
             Interferon/Ribavirin therapy

        Exclusion Criteria:

        Patients who have -

          -  Hepatocellular carcinoma

          -  Co-infection with Hepatitis B virus (HBV) or Human Immunodeficiency Virus (HIV)

          -  Severe or uncontrollable complication
Clinical trial NCT00237913 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: aripiprazole, olanzapine or quetiapine or risperidone
SMILES: ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl, CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical diagnosis of schizophrenia

          -  Schizophrenia symptoms not optimally controlled or antipsychotic medication not well
             tolerated

        Exclusion Criteria:

          -  Diagnosis of schizoaffective disorder

          -  Patients treatment-resistant to antipsychotics
Clinical trial NCT00409851 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: valsartan+amlodipine
SMILES: CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  SUCCESSFUL COMPLETION OF VAA489A2201 CORE TRIAL

          -  VISIT 7 BLOOD PRESSURE MUST BE MSDBP ≤ 95 mmHg AND MSSBP ≤ 150 mmHg

        Exclusion Criteria:

          -  PATIENTS WHO EXPERIENCED ANY ADVERSE EVENTS CONSIDERED SERIOUS AND DRUG RELATED IN
             VAA489A2201 CORE

          -  Other protocol-defined exclusion criteria may apply
Clinical trial NCT00097981 (phase 3, status: completed)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: thalidomide, dexamethasone, doxil
SMILES: CC(C)NCC(O)COC1=CC=CC2=C1C=CC=C2, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  Previously untreated, histologically confirmed multiple myeloma (per International
             Myeloma Working Group [IMWG] criteria

          -  Eastern Cooperative Oncology Group (ECOG) status 0-2

          -  Adequate absolute neutrophil count (ANC), platelet count and hemoglobin

          -  Adequate serum calcium

          -  Enrollment in System for Thalidomide Education and Prescribing Safety Program
             (S.T.E.P.S.)

        Exclusion Criteria:

          -  No treatment with dexamethasone for multiple myeloma

          -  No peripheral neuropathy of Grade 2 or higher

          -  No Left Ventricular Ejection Fraction (LVEF) of less than 45 percentage

          -  No history of life-threatening thromboembolic events of any kind (ie, myocardial
             infarction, pulmonary embolism, stroke or others), within 1 year before enrollment in
             the study

          -  No deep vein thrombosis (DVT) within 1 year of enrollment

          -  No current anticoagulation for DVT
Clinical trial NCT00402532 (phase 3, status: completed)
Conditions: lung transplantation
ICD codes: M31.11
Drugs: everolimus, mycophenolatmofetil
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, COC1=C(C\C=C(/C)CCC(=O)OCCN2CCOCC2)C(O)=C2C(=O)OCC2=C1C
Eligibility criteria:

        Inclusion Criteria:

          -  Recipient of Single or Bilateral Lung Transplantation

          -  Informed consent

          -  Recipients who are able to receive Everolimus at week 3 after Lung Transplantation

          -  women of childbearing potential must have a negative pregnancy test within 48 hours of
             enrolment

          -  women of childbearing potential must use appropriate contraceptive method at
             enrolment, during the study and up to 8 weeks after the end of the study

          -  donor must not have relevant pulmonary diseases

          -  donor must have oxygen partial pressure higher than 300 mmHg at FiO 1.0 and positive
             end-expiratory pressure of 5 cm H2O.

        Exclusion Criteria:

          -  systemic infection of the donor

          -  donor: signs or symptoms of aspiration

          -  donor: severe pulmonary injury or contusion

          -  donor: malignant neoplasm of the lung

          -  donor: HIV positive

          -  recipients who receive immunosuppressive agents not used in this protocol

          -  recipients who participated within 30 days before study start or are currently
             participating in another investigational drug trial

          -  HIV positive recipient

          -  systemic infection of the recipient

          -  recipients of combined/ multiple transplantations

          -  pregnancy of the recipient

          -  recipients with signs/ Symptoms of impaired wound healing of the pulmonary anastomoses

          -  recipients who are still on artificial respiration or who are not able to swallow
             tablets at week 3 after transplantation
Clinical trial NCT00144209 (phase 3, status: completed)
Conditions: restless legs syndrome
ICD codes: G25.81
Drugs: pramipexole, levodopa in combination with benserazide
SMILES: CCCN[C@H]1CCC2=C(C1)SC(N)=N2, C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O
Eligibility criteria:

        Inclusion criteria:

          -  Patients diagnosed with idiopathic restless legs syndrome fulfilling the International
             Diagnostic Criteria 1 .

          -  Male or female patients, aged 25 to 85 years.

          -  Patients presenting RLS symptoms almost every day, as judged by the investigator and
             with more than 5 PLM/h during bedtime in each of three screening actigraphy nights.

          -  Patients must have given written informed consent in accordance with ICH-GCP and local
             legislation prior to participation in the study.

        Exclusion criteria:

          -  Patients with significant diseases other than restless legs syndrome will be excluded.
             A significant disease is defined as a disease that, which in the opinion of the
             investigator may put the patient at a risk because of the participation in the study,
             that may influence the result of the study or the patient's ability to participate or
             that is expected to relevantly reduce life expectancy.

          -  Patients with known hypersensitivity or contraindications to pramipexole, levodopa or
             benserazide or any other substances present in the study medications.

          -  Patients with iron-deficiency

          -  Patients with disabilities or other incapacities that preclude regular attendance at
             clinic for the study visits, and patients on a shift-work-schedule or who are
             otherwise unable to follow a regular sleep-wake cycle.

          -  Patients who have been previously treated with pramipexole or levodopa.

          -  Pregnant or nursing women or women of childbearing age who are at risk of pregnancy
             and are not willing to use adequate contraceptive methods (hormonal contraception or
             intrauterine devices) during the study period.
Clinical trial NCT01015547 (phase 3, status: completed)
Conditions: juvenile idiopathic arthritis
ICD codes: E20.0, I95.0, L50.1, D61.3, G24.2, G24.4, G60.3
Drugs: infliximab plus methotrexate, combination of dmards, methotrexate alone
SMILES: CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  juvenile idiopathic arthritis

          -  arthritis lasting for at least 6 weeks but not more than 6 months

          -  polyarticular disease with at least 5 active joints with at least 3 joints with pain
             or tenderness and limitation of motion

          -  no previous treatment with DMARDs

        Exclusion Criteria:

          -  systemic JIA

          -  any abnormality in the hematopoietic or lymphatic system

          -  any major concurrent medical condition

          -  inadequate psychosocial situation

          -  pregnancy

          -  a non-abstinent female with reproductive capacity without regular contraceptive use
Clinical trial NCT00502996 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: methotrexate, rituximab [mabthera/rituxan]
SMILES: CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients, >=18 years of age;

          -  rheumatoid arthritis >=6 months;

          -  lack of response to 1-5 DMARDs or biological agents;

          -  rheumatoid factor positive.

        Exclusion Criteria:

          -  other chronic inflammatory articular disease or systemic rheumatic disease;

          -  joint or bone surgery during 8 weeks prior to randomization;

          -  previous treatment with any cell-depleting therapy.
Clinical trial NCT01377597 (phase 3, status: completed)
Conditions: retinal vein occlusion
ICD codes: H34.8131, H34.8132, H34.8111, H34.8121, H34.8191, H34.8331, H34.8112
Drugs: ranibizumab
SMILES: CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Japanese patients diagnosed with visual impairment exclusively due to macular edema
             secondary to either branch retinal vein occlusion (BRVO) or central retinal vein
             occlusion (CRVO) Diagnosis within 12 months prior to Visit 1

          -  Best-corrected visual acuity (BCVA):

          -  CRVO: BCVA score ≥24 and ≤73 letters ETDRS (approx. Snellen equivalent of 20/320 and
             20/40) at Visit 1 and 2

          -  BRVO: BCVA score ≥19 and ≤73 letters ETDRS (approx. Snellen equivalent of 20/400 and
             20/40) at Visit 1 and 2

        Exclusion Criteria:

          -  Pregnant or nursing women

          -  History of stroke

          -  Uncontrolled blood pressure

          -  Active ocular infection or intraocular inflammation in either eye

          -  Uncontrolled glaucoma in either eye

          -  Neovascularization of the iris or neovascular glaucoma in either eye

          -  Prior episode of RVO more than 12 months prior to Visit 1 in the study eye

          -  Use of any systemic anti-VEGF drugs within 6 months prior to Visit 2

          -  Prior treatment with any anti-angiogenic drugs within 3 months prior to Visit 2 in
             either eye

          -  Prior panretinal laser photocoagulation within 3 months prior to Visit 2 in the study
             eye

          -  Prior focal/grid laser photocoagulation within 4 months prior to Visit 2 in the study
             eye

          -  Use of intra-/peri-ocular corticosteroids within 3 months prior to Visit 1 in the
             study eye

          -  Use of any intra-ocular corticosteroid implants in the study eye

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00532155 (phase 3, status: completed)
Conditions: carcinoma, non small cell lung
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: aflibercept (ziv-aflibercept, ave0005, vegf trap, zaltrap®), placebo, docetaxel (taxotere®), dexamethasone (pre- and post-medication for docetaxel)
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Histological/cytological proven locally advanced or metastatic non-small cell lung
             cancer

          -  Disease progression during or after one, and only one, prior anticancer therapy which
             is platinum-based for advanced or metastatic disease

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2

          -  Adequate renal, liver and bone marrow functions

        Exclusion Criteria:

          -  Squamous histology/cytology

          -  Less than 28 days elapsed from prior treatment with radiotherapy, surgery, or
             chemotherapy to the time of randomization

          -  Prior isotope therapy, whole pelvic radiotherapy, or radiotherapy to > 25% of bone
             marrow

          -  Prior docetaxel treatment

          -  Uncontrolled hypertension

        The above information was not intended to contain all considerations relevant to
        participation in a clinical trial.
Clinical trial NCT00445770 (phase 3, status: completed)
Conditions: arthritis, rheumatoid
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: etanercept, etanercept, methotrexate
SMILES: [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@H](CO[N+]([O-])=O)O[N+]([O-])=O, [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@H](CO[N+]([O-])=O)O[N+]([O-])=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Must be Japanese and live in Japan

          -  Must be age 20 to 75 years

          -  Diagnosed less than or equal to 10 years from time of first visit

        Exclusion Criteria:

          -  Anyone who has received etanercept or TNF-inhibitors such as infliximab or adalimumab
             in the past

          -  Patient with other rheumatic diseases or conditions that could predispose the patient
             to infection

          -  Pregnant or lactating women
Clinical trial NCT00156091 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: olanzapine, asenapine
SMILES: CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Completed the short-term trial ( 041021 or 021022)

          -  Continued to meet all demographic and procedural inclusion criteria of the short-term
             trial upon entry into this long-term extension trial

          -  Sign a written informed consent for the 041512 trial.

          -  Demonstrated an acceptable degree of compliance with trial medication in the
             short-term trials in the opinion of the investigator

        Exclusion Criteria:

          -  CGI-S score of greater or equal to 6 ( severely psychotic)

          -  Occurrence(s) of AE or other clinically significant findings that would prohibit their
             continuation

          -  Met any of exclusion criteria regarding medical/psychiatric status listed in the
             short-term trials ( 041021 or 041022)

          -  Met exclusion criteria for medication status in short-term trials except for
             antidepressants and mood stabilizers.
Clinical trial NCT00353912 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: valsartan + amlodipine
SMILES: CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  18 years of age or older.

          -  Moderate to severe high blood pressure. This is defined as a systolic pressure (the
             top number) greater than or equal to 160 mmHg and less than 200 mmHg.

        Exclusion Criteria:

          -  History of allergy or hypersensitivity to ARBs, CCBs, thiazide diuretics

          -  Inability to stop all prior blood pressure medications safely

          -  Systolic BP ≥ 200 mmHg and/or diastolic BP ≥ 120 mmHg

          -  Controlled blood pressure (systolic BP < 140 mmHg) taking more than 3 antihypertensive
             medications at screening

          -  Systolic BP ≥ 140 mmHg and < 180 mmHg taking more than two antihypertensive
             medications at screening

          -  Systolic BP ≥ 180 mmHg taking more than one antihypertensive medication at screening

          -  History of autoimmune diseases

          -  History of multiple drug allergies

          -  Liver disease

          -  Pancreatic injury within 1 year of screening

          -  Evidence of kidney impairment or history of dialysis

          -  Any surgical or medical condition which might alter the absorption, distribution,
             metabolism, or excretion of any drug. This could include currently active gastritis,
             ulcers, or gastrointestinal/rectal bleeding, or urinary tract obstruction.

          -  Women of child-bearing potential (WOCBP), defined as all women physiologically capable
             of becoming pregnant, would be excluded UNLESS they are post-menopausal, surgically
             sterile OR are using acceptable methods of contraception. The use of hormonal
             contraceptives is not allowed

          -  Pregnant or nursing (lactating) women

          -  History of malignancy of any organ system within the past five years

          -  Any severe, life-threatening disease within the past five years

          -  History of drug or alcohol abuse within the last 2 years.

          -  History of stroke, angioplasty, coronary artery bypass graft surgery, heart attack or
             unstable angina

          -  Type 1 diabetes

          -  Poorly controlled Type 2 diabetes

          -  History of heart failure

          -  Arrhythmia

          -  Significant valvular heart disease

          -  Active gout

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00434954 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: exenatide twice daily (bid), premixed insulin aspart twice daily (bid)
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have been treated with diet and exercise and a stable, maximally tolerated dose of
             immediate-release or extended-release metformin, or the combination of metformin (any
             dosage) with sulfonylurea/meglitinides for at least 3 months prior to study start

          -  Have not received thiazolidinediones, or alpha-glucosidase inhibitors for longer than
             2 weeks within 3 months prior to study start, and have not received any insulin
             formulation for more than 14 days (other than in emergency situations) and within 14
             days prior to study start

          -  Have an HbA1c between 6.5% and 10.0%, inclusive

          -  Have a body mass index (BMI) between 25 kg/m^2 and 40 kg/m^2, inclusive

        Exclusion Criteria:

          -  Have type 1 diabetes or known latent autoimmune diabetes in adults

          -  Are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy
             (excluding topical and inhaled preparations) or have received such therapy within 2
             weeks prior to study start

          -  Are receiving treatment for gastrointestinal disease with a drug directly affecting
             gastrointestinal motility (e.g., metoclopramide, cisapride, and chronic macrolide
             antibiotics)

          -  Have used any prescription drug to promote weight loss within 3 months prior to study
             start

          -  Have received treatment within 30 days prior to study start with a drug that has not
             received regulatory approval for any indication at the time of study entry

          -  Have previously completed or withdrawn from this study or any other study
             investigating exenatide or GLP-1 analogs